4D Molecular Therapeutics (FDMT) said Thursday that the US Food and Drug Administration has granted the regenerative medicine advanced therapy designation to 4D-150 for the treatment of diabetic macular edema.

The therapy is designed to provides multi-year sustained delivery of anti-VEGF, aflibercept and anti-VEGF-C, from the retina with a single intravitreal injection, the company said.

The RMAT designation, which is part of the 21st Century Cures Act, was created to expedite the development and review of regenerative medicine therapies, according to the announcement.

Price: 3.33, Change: -0.04, Percent Change: -1.19